Substance P (trifluoroacetate salt)
目录号 : GC44959
An endogenous NK1 receptor agonist
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Substance P is tachykinin neuropeptide that selectively binds to neurokinin 1 (NK1) receptors (Kis = 0.14 and 300 nM for NK1 and NK3, respectively) and has diverse biological activities. It is an endogenous peptide expressed in the central and peripheral nervous systems, including the enteric nervous system and in immune cells. Substance P is released with other neurotransmitters in the dorsal horn of the spinal cord following noxious peripheral stimulation and induces pain through NK1 receptors. The NK1 receptor is internalized following substance P binding, and in a rat hindpaw model of inflammation it is internalized in a greater number of spinal cord neurons following a mechanical or non-noxious stimuli, indicating a role for substance P in inflammation and hyperalgesia. Substance P is also involved in depression, anxiety, seizures, and emesis among other functions.
| Cas No. | SDF | ||
| Canonical SMILES | O=C(N[C@@H](CCCCN)C(N1CCC[C@H]1C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N)=O)CCSC)=O)CC(C)C)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)[C@H]4N(C([C@@H](N)CCCNC(N)=N)=O)CCC4.FC(F)(C(O)=O)F | ||
| 分子式 | C63H98N18O13S•XCF3COOH | 分子量 | 1347.6 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7421 mL | 3.7103 mL | 7.4206 mL |
| 5 mM | 0.1484 mL | 0.7421 mL | 1.4841 mL |
| 10 mM | 0.0742 mL | 0.371 mL | 0.7421 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Critical Neurotransmitters in the Neuroimmune Network
Front Immunol 2020 Aug 21;11:1869.PMID:32973771DOI:PMC7472989
Immune cells rely on cell-cell communication to specify and fine-tune their responses. They express an extensive network of cell communication modes, including a vast repertoire of cell surface and transmembrane receptors and ligands, membrane vesicles, junctions, ligand and voltage-gated ion channels, and transporters. During a crosstalk between the nervous system and the immune system these modes of cellular communication and the downstream signal transduction events are influenced by neurotransmitters present in the local tissue environments in an autocrine or paracrine fashion. Neurotransmitters thus influence innate and adaptive immune responses. In addition, immune cells send signals to the brain through cytokines, and are present in the brain to influence neural responses. Altered communication between the nervous and immune systems is emerging as a common feature in neurodegenerative and immunopathological diseases. Here, we present the mechanistic frameworks of immunostimulatory and immunosuppressive effects critical neurotransmitters - dopamine (3,4-dihydroxyphenethylamine), serotonin (5-hydroxytryptamine), Substance P (trifluoroacetate salt powder), and L-glutamate - exert on lymphocytes and non-lymphoid immune cells. Furthermore, we discuss the possible roles neurotransmitter-driven neuroimmune networks play in the pathogenesis of neurodegenerative disorders, autoimmune diseases, cancer, and outline potential clinical implications of balancing neuroimmune crosstalk by therapeutic modulation.